Access Vascular Secures $6M in New Funding

IN.PACT AV Drug-Coated Balloon Is First and Only to Show Superior and Sustained Results Through Two Years Compared to PTA in Treating Arteriovenous Fistulae Lesions

The data, which were presented virtually as a podium first at the 2021 Charing Cross Symposium, demonstrated that the IN.PACT™ AV drug-coated balloon (DCB) is the first and only DCB to show sustained and superior effectiveness through two years compared to standard percutaneous transluminal angioplasty (PTA) in end-stage renal disease (ESRD) patients with de novo or non-stented restenotic native arteriovenous fistulae (AVF) in the upper extremity.

Martell Diagnostic Laboratories Announces HERTEST: Groundbreaking Way to Detect Effectiveness of Breast Cancer RX Globally

HERTEST is a blood test that looks for a protein called human epidermal growth factor receptor (HER2), which is shed into the blood stream of patients with growing breast cancer tumors.

ESPRIT CAM Improves Productivity for Long Part Machining by Automating Multi-spindle Program Creation

ESPRIT CAM: New computer-aided-manufacturing (CAM) technology has been introduced by ESPRIT CAM, part of Hexagon’s Manufacturing Intelligence division that provides manufacturers with the control and flexibility needed to use multi-spindle and multi-channel computer-numerical-control (CNC) machinery for the machining of long parts.

Today Access Vascular announced $6M in new funding from new and existing investors. With this new round, Access Vascular is poised to launch the next generation of its FDA-cleared HydroPICC device, initiate the company’s first post-market registry study, and expedite new product development.

“2020 is shaping up to be another exciting year for Access Vascular,” commented James Biggins, Access Vascular’s Founder and CEO. He emphasized the importance of clinical evidence to the company’s long-term strategy, noting, “While we’ve received incredible traction from doctors and nurses already, we recognize that this is a market which is sorely lacking robust clinical data about patient outcomes. To that end, we intend to conduct multiple clinical evaluations starting in early 2020 that will establish the impact our devices have on patient outcomes compared to conventional catheters.”

The new funding will also support product development as the company seeks to expand its portfolio of reduced thrombosis intravenous devices. The company anticipates making an FDA submission for a second product next year. While Access Vascular’s biomaterial platform has already demonstrated its ability to minimize thrombus accumulation, a leading cause of catheter failure, future innovations in the company’s pipeline could actively combat bloodstream infections for the life of the catheter or allow insertion of a catheter through difficult or stenosed vessels.

 

spot_img

DON'T MISS

Related Articles